Table 2 Indications for linezolid use. Data from the national point prevalence surveys 2011 and 2016. Data comparison of the two surveys
Indication | Variable | Site of infection | Number (percentage) | p-value | |
|---|---|---|---|---|---|
PPS 2011 | PPS 2016 | ||||
All | Total | Â | 119 (100) | 255 (100) | n.a. |
Treatment (CI + LI + HI) | Total |  | 104 (87.4) | 232 (91.0) | 0.29 |
Site of infection (CI+ LI+ HI) | All | 104 (100) | 232 (100) | Â | |
Bacteremia | 10 (9.6) | 27 (11.6) | 0.38 (a) | ||
Non-laboratory confirmed systemic infection | 9 (8.7) | 18 (7.8) | |||
Bone/Joint infection | 10 (9.6) | 28 (12.1) | |||
Skin/Soft tissue infection | 21 (20.2) | 55 (23.7) | |||
Intraabdominal infection | 5 (4.8) | 23 (9.9) | |||
Lower respiratory tract infection | 27 (26.0) | 42 (18.1) | |||
Urinary tract infection | 4 (3.8) | 12 (5.2) | |||
Other/Not specified | 18 (17.3) | 27 (11.6) | |||
Treatment CI + LI | Total |  | 43 (36.1) | 103 (40.4) | 0.44 |
Site of infection (CI + LI) | All | 43 (100) | 103 (100) |  | |
Bacteremia | 3 (7.0) | 9 (8.7) | 0.21 (a) | ||
Non-laboratory confirmed systemic infection | 4 (9.3) | 5 (4.9) | |||
Bone/Joint infection | 4 (9.3) | 11 (10.7) | |||
Skin/Soft tissue infection | 8 (18.6) | 28 (27.2) | |||
Intraabdominal infection | 0 (0) | 11 (10.7) | |||
Lower respiratory infection | 13 (30.2) | 19 (18.4) | |||
Urinary tract infection | 2 (4.7) | 6 (5.8) | |||
Other/Not specified | 9 (20.9) | 14 (13.6) | |||
Treatment HI | Total | Â | 61 (51.3) | 129 (50.6) | 0.90 |
Site of infection (HI) | All | 61 (100) | 129 (100) | Â | |
Bacteremia | 7 (11.5) | 18 (14.0) | 0.94 (a) | ||
Non-laboratory confirmed systemic infection | 5 (8.2) | 13 (10.1) | |||
Bone/Joint infection | 6 (9.8) | 17 (13.2) | |||
Skin/Soft tissue infection | 13 (21.3) | 27 (20.9) | |||
Intraabdominal infection | 5 (8.2) | 12 (9.3) | |||
Lower respiratory infection | 14 (23.0) | 23 (17.8) | |||
Urinary tract infection | 2 (3.3) | 6 (4.7) | |||
Other/Not specified | 9 (14.8) | 13 (10.1) | |||
Other/Unknown | Â | Â | 15 (12.6) | 23 (9.0) | 0.29 |